Navitor Pharmaceuticals to Present at the 30th Annual Piper Jaffray Healthcare Conference
CAMBRIDGE, Mass.--(BUSINESS WIRE)--Nov 20, 2018--Navitor Pharmaceuticals, Inc., a biopharmaceutical company developing innovative therapeutics targeting the activity of mTORC1, or Complex 1 of the mechanistic target of rapamycin, for neurological disorders and chronic diseases of aging, today announced that Thomas E. Hughes, Ph.D., Chief Executive Officer, will present a corporate overview at the 30th Annual Piper Jaffray Healthcare Conference in New York on Tuesday, November 27, 2018 at 1:10 p.m. Eastern time.
Navitor Pharmaceuticals, Inc.is realizing the potential of modulating mTORC1, a master regulator of cellular metabolism, to develop a pipeline of therapeutics that help patients live longer and healthier lives. Our industry-leading team is unlocking the promise of recent discoveries in mTORC1 biology to address a broad range of chronic diseases. Our initial clinical application is a first-in-class drug to address unmet needs in severe depression. For more information, please visit www.navitorpharma.com.
View source version on businesswire.com:https://www.businesswire.com/news/home/20181120005702/en/
CONTACT: Argot Partners
KEYWORD: UNITED STATES NORTH AMERICA MASSACHUSETTS NEW YORK
INDUSTRY KEYWORD: HEALTH BIOTECHNOLOGY MENTAL HEALTH PHARMACEUTICAL
SOURCE: Navitor Pharmaceuticals, Inc.
Copyright Business Wire 2018.
PUB: 11/20/2018 04:05 PM/DISC: 11/20/2018 04:05 PM